ANHYDROUS CITRIC ACID

Details

Stereochemistry	ACHIRAL
Molecular Formula	C6H8O7
Molecular Weight	192.1235
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

OC(=O)CC(O)(CC(O)=O)C(O)=O

InChI

InChIKey=KRKNYBCHXYNGOX-UHFFFAOYSA-N

InChI=1S/C6H8O7/c7-3(8)1-6(13,5(11)12)2-4(9)10/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)

HIDE SMILES / InChI

Molecular Formula	C6H8O7
Molecular Weight	192.1235
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Potassium citrate is indicated for the management of renal tubular acidosis with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, uric acid lithiasis with or without calcium stones. WhenPotassium citrate is given orally, the metabolism of absorbed citrate produces an alkaline load. The induced alkaline load in turn increases urinary pH and raises urinary citrate by augmenting citrate clearance without measurably altering ultrafilterable serum citrate. Thus, potassium citrate therapy appears to increase urinary citrate principally by modifying the renal handling of citrate, rather than by increasing the filtered load of citrate. Potassium citrate is used as a food additive (E 332) to regulate acidity.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
response to acidic pH 16	Interacts 323

Conditions

Condition	Modality	Targets	Highest Phase	Product
Renal tubular acidosis 16	Primary		Approved 8,429	UROCIT-K
Nephrolithiasis 23	Primary		Approved 8,429	UROCIT-K

Doses

Doses

Show entries

Dose	Population	Adverse events
540 mg 1 times / day multiple, oral Recommended	healthy, 24-59 n = 16

Showing 1 to 1 of 1 entries

Previous1Next

Sourcing

Sourcing

Show entries

Vendor/Aggregator	ID	URL
001 Chemical	DY41878	https://www.001chemical.com/chem/77-92-9
3B Scientific (Wuhan) Corp	3B1-00227	http://www.3bsc.com/index/pro_info.php?id=20439
AA Blocks	AA0038YF	http://www.aablocks.com/goods/Goods/detail?id=AA0038YF
AK Scientific, Inc. (AKSCI)	K376	http://www.aksci.com/item_detail.php?cat=K376
Aaron Chemicals	AR0039Q7	http://www.aaronchem.com/77-92-9

Showing 1 to 5 of 109 entries

Previous1 2 3 4 5…22Next

PubMed

Show entries

Title	Date	PubMed
Comparative efficacy of "specific" potassium citrate therapy versus conservative management in nephrolithiasis of mild to moderate severity.	1985 Oct	3897582
Renal hypouricemia due to enhanced tubular secretion of urate associated with urolithiasis: successful treatment of urolithiasis by alkalization of urine K+, Na(+)-citrate.	1993	8302413
[Therapeutic use of potassium citrate].	2001	11475849
Evaluation of aggregating brain cell cultures for the detection of acute organ-specific toxicity.	2013 Jun	22954530

Showing 1 to 4 of 4 entries

Previous1Next

Patents

Sample Use Guides

In Vivo Use Guide

Objective: To restore normal urinary citrate (greater than 320 mg/day and as close to the normal mean of 640 mg/day as possible), and to increase urinary pH to a level of 6.0 to 7.0. • Severe hypocitraturia (urinary citrate < 150 mg/day): therapy should be initiated at 60 mEq per day; a dose of 30 mEq two times per day or 20 mEq three times per day with meals or within 30 minutes after meals or bedtime snack • Mild to moderate hypocitraturia (urinary citrate >150 mg/day): therapy should be initiated at 30 mEq per day; a dose of 15 mEq two times per day or 10 mEq three times per day with meals or within 30 minutes after meals or bedtime snack

Route of Administration: Oral

In Vitro Use Guide

Unknown